US FDA approves AstraZeneca’s new breast cancer pill Etcamah: Dosage, high risk and side effects — All you need to know

livemint.com · 2026-09-05

The drug, known as camizestrant, can be used in combination with other cancer medicines in patients who have a genetically driven form of metastatic breast cancer. AstraZeneca said camizestrant, which will go by the brand name ETCAMAH.

TickrTrends take: AstraZeneca received FDA approval for Etcamah, a new breast cancer treatment, which expands its oncology portfolio and potential revenue streams in a high-demand therapeutic area. Given TickrTrends' current undervalued assessment of AZN, investors focused on valuation should monitor how this approval translates into near-term sales figures and long-term market penetration in the competitive breast cancer treatment segment. The commercial success of Etcamah could be a material factor in validating or adjusting the current undervaluation thesis for the Healthcare sector company.

Read the full story at livemint.com →